2012 Annual Meeting of the Consortium of Multiple Sclerosis
The focus of the 2012 Annual Meeting of the CMSC is "to provide MS healthcare professionals with the most up-to-date information impacting patient care in the areas of research, disease modification, epidemiology, quality of life, neuroimaging, gender specific issues..." and more. Highlights from the conference will include case-based learning, technological advances in clinical care and research, clinical care, and basic research and clinical trials.
CMSC 2012: Immune Parameters Normalize Within 4 Months of Natalizumab Cessation in the Treatment of RRMS
CMSC 2012: Dimethyl Fumarate Improves Annualized Relapse Rate and Risk of Relapse in Patients With RRMS
CMSC 2012: Fingolimod Significantly Reduces Relapse Rates in MS Patients, Regardless of Duration of or Reasons for Discontinuing Prior Therapy